Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BCMA-targeting therapy

- PMLiVE

EMA concludes GSK, Vir’s mAb can be used to treat high-risk COVID-19 patients

Recommendations can be used to support national advice prior to marketing authorisation

- PMLiVE

Sandoz to acquire GSK’s cephalosporin antibiotic brands for up to $500m

Sandoz, the generics division of Novartis, will pay $350m upfront for three established brands

- PMLiVE

FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions

Inspection of third-party manufacturing plant delayed due to COVID-19

- PMLiVE

GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2

Treatment could be transformative for around 260 million people living with disease

- PMLiVE

Medicago doses first patients with plant-derived COVID-19 vaccine

Study will evaluate candidate alone or in combination with an adjuvant

- PMLiVE

Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

The five-year deal includes Sitryx’ two lead projects

- PMLiVE

China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

China secures a place at the forefront of innovative medicine

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

GlaxoSmithKline reportedly looking to sell select antibiotic brands

Sale would fund R&D efforts in other key focus areas such as oncology

- PMLiVE

Moderna and GSK advance coronavirus vaccine candidates

Developments come amid rapidly growing cases across the globe

- PMLiVE

Researchers discover new antibiotic using AI

First antibiotic to be discovered using this method

- PMLiVE

FDA begins speedy review of BMS’ CAR-T liso-cel

Agency sets target action date of 17 August for final decision

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links